*March 2020* A biopsy sample of tissue often is tested for specific genetic variations (also referred to as mutations) that may

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC);

*March 2020* Targeted sequencing of patients with acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR T790M-mutant non-small

*February 2020* Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate

*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a

*March 2020* Osimertinib (Tagrisso) is the standard frontline therapy for patients with metastatic, EGFR-mutant non–small cell lung cancer (NSCLC), and although

*January 2020* Among 62 patients who met eligibility critieria, histologic transformation, primarily squamous transformation, was identified in 15% of first-line

*February 2020* Positive news for METex14 mutated NSCLC patients. Note this is also good news for patients with EGFR-Independent acquired

*January 2020* Researchers in the Center for Cancer Research have found that circulating lymphocytes can be stimulated in the laboratory

*December 2019* Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to